Harrow.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ...
Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...
Harrow Inc (NASDAQ:HROW) and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement on Monday. Harrow acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ...
Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.
Graduates from 12 nationalities earn places at top universities across the UK, USA, Japan, Canada, Australia and beyond — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results